The aim of this study was to determine the expression of human epidermal growth factor receptor type 2 HER2 , epidermal growth factor receptor EGFR , peroxisome proliferator-activated receptor PPAR , CD44 and androgen receptor AR in adenoid cystic carcinomas ACC , carcinoma ex pleomorphic adenomas CXPA and mucoepidermoid carcinomas MEC of the salivary glands, to investigate their molecular difference and to estimate the availability of molecular-targeted and hormonal therapy in salivary-gland tumors. Forthy patients with a salivary gland tumor, diagnosed and treated at our hospital, were studied. On the basis of histopathology, 10, 19 and 11 patients were identi ed with ACC, CXPA and MEC, respectively. The associations between histological types were evaluated by the chi-square test. Differences were considered statistically signi cant at P 0.05. HER2positive expression was observed in 10% of ACC, 84% of CXPA and 18% of MEC. EGFR-positive expression was observed in 40% of ACC, 68% of CXPA and 91% of MEC. CD44-positive expression was observed in 40% of ACC, 47% of CXPA and 91% of MEC. PPAR -positive expression was observed in 10% of ACC, 53% of CXPA and 18% of MEC. AR-positive expression was observed in 20% of ACC, 32% of CXPA and 9% of MEC. Compared with other histological types, CXPA demonstrated signi cant HER2 and PPAR staining and MEC demonstrated significant EGFR and CD44 staining. The differences in expression of markers between histological types in our study suggests the possibility that HER2-and PPAR -targeted therapy may be effective in CXPA, and that EGFR-target therapy may be effective in MEC of the salivary glands.
Introduction
Tumors of the salivary glands account for 5% of all neoplasms of the head and neck 1 .
These tumors arise primarily in the parotid gland, occasionally in the submandibular and intraoral glands, and rarely in the sublingual glands 1 . Approximately 25% of tumors in the parotid gland and 50% of tumors in the other salivary glands are malignant 2 . There are various histological types of the malignant neoplasm of the salivary glands. These include adenoid cystic carcinomas ACC , carcinoma ex pleomorphic adenomas CXPA and mucoepidermoid carcinomas MEC , which account for approximately 5% of salivary gland neoplasms. Other histological types are uncommon.
Surgical resection is the primary treatment of neoplasms of the salivary gland at initial diagnosis. Radiation therapy is usually administered to patients with advanced disease, inadequate margins and those who exhibit poor prognostic features such as perineural invasion or anaplastic histology 3 . Chemotherapy has generally been reserved for patients with incurable salivary neoplasms. The typical treatment-response rate of patients with salivary gland tumors is 15 -30%, and patients usually have a short survival period. The most active single agents include cisplatin, cyclophosphamide, doxorubicin and 5-uorouracil. There is a de nite need for additional therapeutic strategies to improve the survival and quality of life for these patients.
Molecular-targeted therapy and hormonal therapy are impacting positively on the daily practice of clinical oncology and are potential treatment strategies for this patient group.
Tumor biomarker overexpression also has therapeutic implications. Several studies have demonstrated the in vitro and in vivo ef cacy of some antibodies on human cancers. Those that are efficacious include human epidermal growth factor receptor type 2 HER2 in breast cancer 4 , epidermal growth factor receptor EGFR in colon cancer 5 , CD44 in head and neck squamous cell carcinoma cells 6 , peroxisome proliferator activated receptor PPAR in bladder tumor cells 7 , and androgen receptor AR in prostate cancer 8 . The purpose of the present study was to determine the expression of HER2, EGFR, PPAR , CD44 and AR in ACC, CXPA and MEC of the salivary glands, to investigate the difference in their expression and to estimate the ef cacy of molecular-targeted and hormonal therapy in salivary gland tumors.
Materials and Methods

Patients and samples
This study included 40 patients diagnosed and treated for a primary malignant salivary gland tumor at our hospital since 1990. All patients underwent surgical resection of the tumor. On the basis of histopathology, 10, 19 and 11 patients were identi ed with ACC, CXPA and MEC, respectively.
Immunohistological staining
For the immunohistochemical staining for HER2 clone CB11 ; Ventana, Tucson, AZ, were incubated with Tris-EDTA buffer pH 9.0 for 30 minutes. In each case, nonspeci c immunoreactivity was blocked by incubation with normal donkey serum for 30 min. The sections were then incubated with primary antibody for 30 minutes. After washing with phosphate-buffered saline PBS three times, each for 5 min, the sections were incubated for 60 min with the multilink biotinylated anti-immunoglobulin. They were then washed with PBS three times, each for 5 min, before and after being treated with streptavidin-peroxidase reagent for 30 min. The reactions were visualized with diaminobenzidine Dako as a chromogen. All steps were followed by adequate washes in PBS. Finally, sections were counterstained with hematoxylin, dehydrated and mounted.
Scoring
The intensity of the immunoreactions negative, positive was assessed for each case. For HER2, EGFR and CD44, expression was considered positive only if distinct membranous immunoreactivity was present. The tumors in which immunoreactive tumor cells constituted 10% of the tumor were graded as positive 9, 10 . PPAR expression was considered positive only if distinct cytoplasmic immunoreactivity was present. The tumors in which immunoreactive tumor cells constituted 20% of the tumor were graded as positive 11 . AR expression was considered positive only if distinct nuclear immunoreactivity was present.
The tumors in which immunoreactive tumor cells constituted 10% of the tumor were graded as positive 12 .
All slides were evaluated independently by at least two investigators.
Analysis
The associations between histological types were evaluated by the chi-square test. Differences were considered statistically signi cant at P 0.05. Table 1 .
Results
HER2-positive expression was observed in
Discussion
Additional strategies are required to improve the survival and quality of life of patients with salivary gland tumors. In several other tumors, molecular targeted therapy with antibodies or antagonists and hormonal therapy are promising therapeutic strategies. Some reports indicate that the appearance rates of these markers are re ected in the therapeutic gain in vitro and in vivo.
In breast cancer patients, HER2-overexpressing tumors are responsive to trastuzumab both as a single agent and in combination with other chemotherapeutic agents 4 . Matsui et than for those AR-positive patients who did not receive hormone therapy after primary radical surgery for breast cancer. In the present study, AR-expression levels were low in all three histological types ; therefore, the ef cacy of AR-targeted therapy for these tumors is yet to be established.
Recent studies have reported that the markers evaluated in our study are associated with carcinogenesis and tumor proliferation in salivary gland tumors, and the ef cacy of targeted therapy for salivary gland tumors has been suggested 9, 11, 25, 26 . Haddad et al 25 The present study is the rst to evaluate PPAR expression in ACC, CXPA and MEC.
Mukunyadzi et al 11 reported expression levels of PPAR in 15 salivary duct carcinomas SDC . They found no correlation between PPAR expression and tumor stage, recurrence or survival, but that PPAR is a potential target site for therapeutic manipulation.
Sugut et al 28 reported the expression levels of AR in four acinic cell carcinomas, seven adenocarcinomas not otherwise specified NOS , 13 ACC, two CXPA, seven MEC and three SDC. They found that AR was expressed in three of four SDCs, two of seven adenocarcinomas NOS and one of two CXPA, but no immunoreactivity was observed in 13 ACC, seven MEC, or four acinic-cell carcinomas. Although there were only two CXPA in the present series, the results of our report were consistent with previous reports and suggest that the expression of AR in high-grade salivary gland tumors may be used in the clinical management of these neoplasms. However, Fan et al 29 examined the expression of AR in 13 SDC and observed strong immunostaining for AR in all cases. They suggested that antiandrogen therapy used in the treatment of prostatic carcinomas may also be benecial in patients with SDC.
Previous reports have suggested the potential effectiveness of HER2-targeted therapy in patients with CXPA and of EGFR-targeted therapy in patients with MEC. Furthermore, the effectiveness of PPAR in CXPA and CD44 in MEC has been speculated. By examining the expression of these markers it is possible to select those patients who would best respond to targeted therapies, and to identify markers associated with effective therapy.
Concurrent therapy using combined targeted therapies and improved treatment regimens would result in the effective treatment of patients with salivary gland tumors.
In summary, we investigated the expression of HER2, EGFR, CD44, PPAR and AR in salivary gland tumors. Differences in the expression of markers between the various histological types indicate the ef cacy of targeted therapy of salivary gland tumors.
